Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Syros Pharmaceuticals stock
Learn how to easily invest in Syros Pharmaceuticals stock.
Syros Pharmaceuticals Inc is a biotechnology business based in the US. Syros Pharmaceuticals shares (SYRS) are listed on the NASDAQ and all prices are listed in US Dollars. Syros Pharmaceuticals employs 124 staff and has a trailing 12-month revenue of around $25.2 million.
How to buy shares in Syros Pharmaceuticals
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – SYRS – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Syros Pharmaceuticals stock price (NASDAQ: SYRS)Use our graph to track the performance of SYRS stocks over time.
Syros Pharmaceuticals shares at a glance
|Latest market close||$6.64|
|52-week range||$5.25 - $48.00|
|50-day moving average||$7.88|
|200-day moving average||$13.12|
|Wall St. target price||$43.40|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-1.55|
Buy Syros Pharmaceuticals shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Syros Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Syros Pharmaceuticals price performance over time
|1 week (2022-09-28)||19.42%|
|1 month (2022-09-02)||749.65%|
|3 months (2022-07-05)||663.22%|
|6 months (2022-04-04)||457.98%|
|1 year (2021-10-05)||54.06%|
|2 years (2020-10-05)||-26.55%|
|3 years (2019-10-04)||8.7|
|5 years (2017-10-05)||16.58|
Syros Pharmaceuticals financials
|Revenue TTM||$25.2 million|
|Gross profit TTM||$23.5 million|
|Return on assets TTM||-39.15%|
|Return on equity TTM||-135.99%|
|Market capitalisation||$130.7 million|
TTM: trailing 12 months
Syros Pharmaceuticals share dividends
We're not expecting Syros Pharmaceuticals to pay a dividend over the next 12 months.
Have Syros Pharmaceuticals's shares ever split?
Syros Pharmaceuticals's shares were split on a 1:10 basis on 18 September 2022. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Syros Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Syros Pharmaceuticals shares which in turn could have impacted Syros Pharmaceuticals's share price.
Syros Pharmaceuticals share price volatility
Over the last 12 months, Syros Pharmaceuticals's shares have ranged in value from as little as $5.25 up to $48. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Syros Pharmaceuticals's is 1.6101. This would suggest that Syros Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Syros Pharmaceuticals overview
Syros Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc.
Syros Pharmaceuticals in the news
Syros Pharmaceuticals, Inc. (SYRS) Upgraded to Buy: What Does It Mean for the Stock?
Syros Announces Closing of Merger with Tyme Technologies and Concurrent Private Placement
Syros and Tyme Technologies Announce Stockholder Approval of Merger
Frequently asked questionsWhat percentage of Syros Pharmaceuticals is owned by insiders or institutions?
Currently 5.016% of Syros Pharmaceuticals shares are held by insiders and 61.05% by institutions. How many people work for Syros Pharmaceuticals?
Latest data suggests 124 work at Syros Pharmaceuticals. When does the fiscal year end for Syros Pharmaceuticals?
Syros Pharmaceuticals's fiscal year ends in December. Where is Syros Pharmaceuticals based?
Syros Pharmaceuticals's address is: 35 CambridgePark Drive, Cambridge, MA, United States, 02140 What is Syros Pharmaceuticals's ISIN number?
Syros Pharmaceuticals's international securities identification number is: US87184Q1076 What is Syros Pharmaceuticals's CUSIP number?
Syros Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 87184Q107
More guides on Finder
How to buy YanGuFang International Group (YGF) stock when it goes public
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
What are the FAANG stocks and how do you invest in them?
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
How to buy soccer stocks
A simple guide to buying stocks in your favorite European soccer team.
How to buy Juventus stock
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
How to buy AS Roma stock
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
How to buy Borussia Dortmund stock
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
How to buy Lead Real Estate Co. (LRE) stock when it goes public
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
How to buy Third Harmonic Bio (THRD) stock
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
How to buy LINKBANCORP (LNKB) stock
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
Ask an Expert